190 related articles for article (PubMed ID: 33322932)
1. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
[No Abstract] [Full Text] [Related]
2. Quercetin, Perillyl Alcohol, and Berberine Ameliorate Right Ventricular Disorders in Experimental Pulmonary Arterial Hypertension: Effects on miR-204, miR-27a, Fibrotic, Apoptotic, and Inflammatory Factors.
Rajabi S; Najafipour H; Jafarinejad-Farsangi S; Joukar S; Beik A; Askaripour M; Jafari E; Safi Z
J Cardiovasc Pharmacol; 2021 Jun; 77(6):777-786. PubMed ID: 34016844
[TBL] [Abstract][Full Text] [Related]
3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
4. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
5. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats.
Tang C; Luo Y; Li S; Huang B; Xu S; Li L
Biomed Pharmacother; 2021 Jan; 133():111081. PubMed ID: 33378977
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
Conzatti A; Colombo R; Siqueira R; Campos-Carraro C; Turck P; Luz de Castro A; Belló-Klein A; Sander da Rosa Araujo A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):612-620. PubMed ID: 38547510
[TBL] [Abstract][Full Text] [Related]
8. Effect of estrogen on right ventricular remodeling of monocrotaline-induced pulmonary arterial hypertension in rats and its mechanism.
Liu Z; Duan YL; Ge SL; Zhang CX; Gong WH; Xu JJ
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1742-1750. PubMed ID: 30840299
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
10. Alginate Oligosaccharide Alleviates Monocrotaline-Induced Pulmonary Hypertension via Anti-Oxidant and Anti-Inflammation Pathways in Rats.
Feng W; Hu Y; An N; Feng Z; Liu J; Mou J; Hu T; Guan H; Zhang D; Mao Y
Int Heart J; 2020 Jan; 61(1):160-168. PubMed ID: 31956132
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of aqueous extract of stem bark of Terminalia arjuna (Roxb.), An ayurvedic drug in experimental pulmonary hypertension.
Meghwani H; Prabhakar P; Mohammed SA; Seth S; Hote MP; Banerjee SK; Arava S; Ray R; Maulik SK
J Ethnopharmacol; 2017 Feb; 197():184-194. PubMed ID: 27401289
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
13. The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress, and impaired pulmonary artery reactivity.
Zimmer A; Teixeira RB; Constantin RL; Campos-Carraro C; Aparicio Cordero EA; Ortiz VD; Donatti L; Gonzalez E; Bahr AC; Visioli F; Baldo G; Luz de Castro A; Araujo AS; Belló-Klein A
Eur J Pharmacol; 2021 Jan; 891():173699. PubMed ID: 33160936
[TBL] [Abstract][Full Text] [Related]
14. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
15. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
16. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
Cai C; Xiang Y; Wu Y; Zhu N; Zhao H; Xu J; Lin W; Zeng C
Mol Med Rep; 2019 Dec; 20(6):4984-4992. PubMed ID: 31702810
[TBL] [Abstract][Full Text] [Related]
17. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2019; 122-123():106599. PubMed ID: 31629919
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of baicalin against pulmonary arterial hypertension vascular remodeling through regulation of TNF-α signaling pathway.
Xue X; Zhang S; Jiang W; Wang J; Xin Q; Sun C; Li K; Qi T; Luan Y
Pharmacol Res Perspect; 2021 Feb; 9(1):e00703. PubMed ID: 33421306
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
[TBL] [Abstract][Full Text] [Related]
20. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Chowdhury B; Luu AZ; Luu VZ; Kabir MG; Pan Y; Teoh H; Quan A; Sabongui S; Al-Omran M; Bhatt DL; Mazer CD; Connelly KA; Verma S; Hess DA
Biochem Biophys Res Commun; 2020 Mar; 524(1):50-56. PubMed ID: 31980166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
